ArticleJournal of health economics and outcomes research2026
Cost-Effectiveness Analysis of Trastuzumab-Emtansine as Adjuvant Therapy for HER2-Positive Early Breast Cancer with Residual Invasive Disease in Colombia.
Daniel Samacá-Samacá et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.